MedTrace Logo

Efficacy of Melatonin in Decreasing the Incidence of Delirium in End of Life Patients

NCT02536417 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2021-08-26

No results posted yet for this study

Summary

The purpose of this study is to determine if melatonin administration to end-of-life patients is effective in preventing the development of delirium compared with those who do not receive this treatment. Delirium is a difficult to control symptom commonly seen in patients at the end-of-life. A person who is delirious is unable to think clearly and cannot make sense of what is going on around him/her.

Conditions

  • Delirium

Interventions

DRUG

Melatonin

To determine the effectiveness of melatonin in preventing the development of delirium compared with placebo

DRUG

Sugar pill

To determine if placebo effect plays a part in preventing the development of delirium

Sponsors & Collaborators

  • Fraser Health

    lead OTHER

Principal Investigators

  • David D Ng, PharmD · Fraser Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-29
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02536417 on ClinicalTrials.gov